Informations générales (source: ClinicalTrials.gov)
Origin and Function of Eosinophilic Polynuclear During Drug Reaction With Eosinophilia and Systemic Symptoms (DRESS) Syndrome (DRESSEO)
Observational
University Hospital, Lille (Voir sur ClinicalTrials)
juillet 2020
décembre 2023
26 avril 2025
Drug Hypersensitivity Syndrome or DRESS for "Drug Reaction with Eosinophilia and Systemic
Symptoms" is a serious drug allergy which can be life-threatening for patients with
serious organ damage. The pathophysiology of DRESS is still not fully understood. In
particular, no study has focused on the characterization of eosinophils, while
paradoxically eosinophilia is one of the diagnostic criteria. Likewise, there is no data
about the origin of eosinophils and few data are available concerning immune polarization
of T-cells or the involvement of innate lymphoid cells type 2 in the recruitment of
eosinophils. Our preliminary data on increase activation markers membrane expression of
cutaneous eosinophils suggest that this approach could allow the identification of
endotypes in which eosinophils are involved and contribute to organ damages. The
correlation between tissue infiltration of eosinophils and their degree of activation
would then justify the development of targeted therapeutic strategies in DRESS syndrome
(anti-IL-5 therapy?). The aim of the project is: 1) Evaluate the activation status of
circulating and cutaneous eosinophils in patients with DRESS compared with drug induced
maculopapular exanthema without or with eosinophilia (but do not fulfill DRESS criteria)
and healthy subjects; 2) Understand the pathophysiological mechanisms at the origin of
this eosinophilia.
Etablissements
| Les établissements d'Île-de-France ayant mis à jour leurs données Origine et niveau de fiabilité des données | |||||
|---|---|---|---|---|---|
| HOPITAL FOCH | Matthieu GROH | 05/05/2025 07:12:06 | Contacter | ||
| Les établissements sans correspondance certaine dans le répertoire FINESS dont les données sont issues de ClinicalTrials.gov Origine et niveau de fiabilité des données | |||||
| Assistance Publique - Hôpitaux de Paris - HENRI MONDOR - Créteil - France | Contact (sur clinicalTrials) | ||||
| CH d'Arras - Arras - France | Contact (sur clinicalTrials) | ||||
| CH de Boulogne - Boulogne-sur-Mer - France | Contact (sur clinicalTrials) | ||||
| CH de Douai - Douai - France | Contact (sur clinicalTrials) | ||||
| CH de Dunkerque - Dunkerque - France | Contact (sur clinicalTrials) | ||||
| CH de Roubaix - Roubaix - France | Contact (sur clinicalTrials) | ||||
| CH de Valenciennes - Valenciennes - France | Contact (sur clinicalTrials) | ||||
| CH LENS - Lens - France | Contact (sur clinicalTrials) | ||||
| Groupe Hospitalier de l'Institut Catholique de Lille - Lille - France | Contact (sur clinicalTrials) | ||||
| Hop Claude Huriez Chr Lille - 59000 - Lille - France | Contact (sur clinicalTrials) | ||||
| Hôpital FOCH - Suresnes - France | Contact (sur clinicalTrials) | ||||
Critères
Tous
Inclusion Criteria:
Group 1 (DRESS): adult with a diagnosis of DRESS based on the following four criteria:
- Cutaneous rash occurring at least 24 hours and at most 2 months after continuous
medication use
- Fever over 38 degre celcius
- At least one organ dysfunction among:
- Lymphadenopathy
- hepatitis
- Pulmonary involvement
- Cardiac involvement: myocarditis, pericarditis
- Renal impairment
- At least one of the following hematological anomalies:
- Eosinophilia ≥ 500 / mm3 .
- RegiSCAR Score ≥ 4
Groups 2 and 3 (Drug induced maculopapular exanthema without or with eosinophilia).
- Adult with drug-induced rash
- Without clinical criteria of severity defined by Djien among :
- An evolution of more than 21 days
- with organ damage as defined in group 1
Group 2 (MPE without eosinophilia): blood eosinophils < 500 / mm3
Group 3 (MPE with eosinophilia): blood eosinophils ≥ 500 / mm3
Group 1 (DRESS): adult with a diagnosis of DRESS based on the following four criteria:
- Cutaneous rash occurring at least 24 hours and at most 2 months after continuous
medication use
- Fever over 38 degre celcius
- At least one organ dysfunction among:
- Lymphadenopathy
- hepatitis
- Pulmonary involvement
- Cardiac involvement: myocarditis, pericarditis
- Renal impairment
- At least one of the following hematological anomalies:
- Eosinophilia ≥ 500 / mm3 .
- RegiSCAR Score ≥ 4
Groups 2 and 3 (Drug induced maculopapular exanthema without or with eosinophilia).
- Adult with drug-induced rash
- Without clinical criteria of severity defined by Djien among :
- An evolution of more than 21 days
- with organ damage as defined in group 1
Group 2 (MPE without eosinophilia): blood eosinophils < 500 / mm3
Group 3 (MPE with eosinophilia): blood eosinophils ≥ 500 / mm3
- Other cause of eosinophilia including cancer, blood disease before the introduction
of suspected molecule(s).
- On going oral or local corticosteroid therapy, anti-leukotriene therapy
(MONTELUKAST) by the month preceding the study;
- Anti-IgE therapy (OMALIZUMAB, LIGELIZUMAB), anti-IL-5 therapy (MEPOLIZUMAB,
BENRALIZUMAB) or anti-IL4 and / or anti-IL13 therapy (DUPILUMAB, TRALOKINUMAB) in
the 6 months preceding the study.
- Any pregnant or lactating woman.
- Contraindication related to the blood volume taken for the study.